After 3.5 years of follow-up, there was a 98% rate of minimal residual disease, and 9 patients were still in complete remission.

R1vascular (R1vasc) resection surgery leads to similar survival outcomes as R0 resection (median: 54 months vs 65 months) in patients with challenging mass-forming cholangiocarcinoma (MF-CCA), an ...

Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.

HealthDay News — Some commonly prescribed photosensitizing drugs increase skin cancer risk, according to a study published online March 18 in Photodermatology, Photoimmunology & Photomedicine.

This is the first trial to prospectively demonstrate the impact of bone-protecting agents use on fracture risk for men receiving an androgen receptor pathway inhibitor.

Barriers contributing to underreporting of fatigue also include belief that symptom is sign disease is progressing and attempt to be a “good patient.” ...

HealthDay News — A high proportion of women seem to undergo mammography screening every year, despite recommendations for biennial screening, according to a research letter published online March 25 ...

The researchers concluded that slower turnaround time for biomarker testing is associated with early non-targeted treatment in patients with ALK +/ EGFR + advanced NSCLC, a practice that is “common,” ...

Researchers sought to determine whether mosunetuzumab would have long-term efficacy in patients with follicular lymphoma.

An observational study identified light-intensity physical activity and Karnofsky Performance Scale as common characteristics in better functional quality of life for patients with pulmonary and ...

Updated phase 3 data support pembrolizumab plus concurrent chemoradiotherapy as a standard of care for patients with high-risk, locally advanced cervical cancer, according to Linda Duska, MD.

Researchers sought to test the performance of a deep learning model system using longitudinal magnetic resonance imaging (MRI) in predicting early recurrence in patients with hepatocellular carcinoma.